

PERNIX THERAPEUTICS HOLDINGS, INC.

Form 8-K

April 05, 2016

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2016

PERNIX THERAPEUTICS HOLDINGS, INC.  
(Exact name of registrant as specified in its charter)

Maryland                                      001-14494                                      33-0724736  
(State or other jurisdiction                      (Commission File Number)                      (IRS Employer Identification No.)  
of incorporation)

10 North Park Place, Suite 201  
Morristown, NJ                                      07960  
(Address of principal executive offices)                      (Zip Code)

Registrant's telephone number, including area code: (800) 793-2145

---

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On March 31, 2016 Rick Shalaby resigned as Senior Vice President of Commercial Operations of Pernix Therapeutics Holdings, Inc. (the “Company”). Mr. Shalaby’s resignation will be effective April 8, 2016. Doug Drysdale, the Company’s Chief Executive Officer, and Terry Novak, the Company’s Chief Operating Officer, will assume Mr. Shalaby’s responsibilities until the Company hires a replacement for Mr. Shalaby. Mr. Shalaby is leaving the Company on good terms and there was no disagreement between Mr. Shalaby and the Company on any matters related to the Company’s operations, policies or practices. The Company thanks Mr. Shalaby for his contributions during his term with the Company.



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PERNIX  
THERAPEUTICS  
HOLDINGS, INC.

Dated: April 5, 2016 By: /s/ Sanjay Patel  
Sanjay Patel  
Chief Financial Officer